The COVID pandemic accelerated something that had been developing slowly for years. When site-based trials became impossible or impractical during lockdowns, sponsors scrambled to move as much as possible to remote participation — and found that much of it worked. The result is a category of trials now designed from the start around minimizing travel requirements.
I've tracked this shift closely through the trial data on this platform. Decentralized elements are now common even in trials that don't describe themselves as fully decentralized — remote visits for check-ins, wearable devices for data collection, home delivery of study medication.
What "decentralized" actually means
Fully decentralized trials aim to have zero in-person visits. All assessments happen via telehealth, home nursing visits, local lab work arranged by the study team, and wearable sensors. The investigational medication is shipped directly to participants. This model is feasible for certain types of studies — particularly those involving oral medications and standard monitoring parameters — but not for all.
Hybrid trials — the more common version — have some in-person requirements (often screening, the first dosing visit, and end-of-study) while moving routine monitoring visits to remote formats. This dramatically reduces the total number of times you need to travel without eliminating all site contact.
What happens in a home visit
Many decentralized trials include home nursing visits for assessments that require a trained professional — blood draws, vital sign measurements, physical examinations. A nurse contracted by the study team comes to your home at a scheduled time. This sounds unusual, but in practice most participants find it far less disruptive than traveling to a clinic.
The nurse uses the same procedures and documentation standards as site visits. The data collected is transmitted directly to the study database. It's not a different standard of care — it's the same procedures in a different location.
Wearables and remote monitoring
Many decentralized trials use wearable devices — accelerometers, continuous glucose monitors, ECG patches, smart inhalers — to collect data continuously between visits. You'll be asked to wear the device for specified periods and return it or sync data at intervals.
Ask specifically what data the device collects and where it goes. Health data collected by devices belongs to the study — understand what that means for privacy before you agree. The consent form's data section should explain this, but it's worth asking for plain-language clarification.
What still typically requires in-person visits
Screening and eligibility verification are almost always done in person — the team needs a physical examination and controlled test conditions. Any visit involving imaging (MRI, CT, PET) stays at the imaging center. Procedures like infusions, lumbar punctures, or biopsies can't be done at home. The end-of-study visit is often in-person for a comprehensive safety assessment.
Ask for a clear list of which visits are remote-eligible and which require travel. If the "decentralized" trial still has 8 in-person visits, that's useful information for your planning.
Technical requirements
Most decentralized trials use a study-specific app or platform for telehealth visits, eDiary (electronic daily symptom reporting), and communication with the study team. The sponsor typically provides the devices needed, or specifies minimum requirements for your own smartphone or tablet. Don't assume your current devices will work — confirm before screening.